Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CTSE | P14091 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5895776 | 0.86 | TSHR (0.38) | TSHRALOX15USP2SMN1; SMN2DDB1 | |
| SCHEMBL5896565 | 0.85 | ALOX15 (0.35) | TSHRALOX15ATMUSP2SMN1; SMN2 | |
| SCHEMBL5895338 | 0.83 | GPR4 (0.37) | TSHRALOX15USP2SMN1; SMN2DDB1 | |
| SCHEMBL5895185 | 0.77 | TSHR (0.39) | TSHRALOX15ATMUSP2SMN1; SMN2 | |
| SCHEMBL5895921 | 0.76 | TSHR (0.38) | TSHRALOX15ATMUSP2SMN1; SMN2 | |
| SCHEMBL5895569 | 0.74 | TSHR (0.36) | TSHRALOX15USP2SMN1; SMN2DDB1 | |
| SCHEMBL5896071 | 0.74 | ALOX15 (0.36) | TSHRALOX15USP2SMN1; SMN2DDB1 | |
| SCHEMBL5895808 | 0.73 | GPR4 (0.37) | TSHRALOX15USP2SMN1; SMN2DDB1 | |
| SCHEMBL5896118 | 0.72 | TSHR (0.35) | TSHRALOX15USP2SMN1; SMN2DDB1 | |
| SCHEMBL5895323 | 0.71 | USP2 (0.47) | TSHRALOX15ATMUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR5, CXCR1, ACKR3 | TSHR 1067/4885ALOX15 2537/4885ATM 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.